Remove Cholesterol Remove Obesity Remove Public Health
article thumbnail

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation

The AHA strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives.

article thumbnail

Global Trends in Cardiovascular Diseases: Insights from the 2023 Almanac

Cardiology Update

Growing Global Burden of Cardiometabolic Risks: The 2023 World Obesity Atlas projects a significant rise in global overweight and obesity levels by 2035, leading to a surge in diabetes cases. The findings have significant implications for clinical and public health practice and research.

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

Food and Drug Administration ( FDA ) has approved an additional indication for Wegovy ( semaglutide ) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.

Obesity 111
article thumbnail

Researchers Find ApoB Test May be More Accurate Measure of Heart Disease Risk

DAIC

13, 2024 – The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for many Americans, according to a study led by UT Southwestern Medical Center researchers and published in JAMA Cardiology. School of Public Health at UT Southwestern. Ann Marie Navar, M.D., population.